Skip to main content

Casdin Capital — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

95
Companies
$6.8B
Total invested
$71.7M
Avg. check
24
Industries
Biotechnology 20Health Care 15Therapeutics 9Life Science 8Medical 7Artificial Intelligence (AI) 5+18 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 95
Hexagon Bio
October 2026

Hexagon Bio discovers and develops new cancer therapies using microbial natural products, genomic data, and artificial intelligence.

Artificial Intelligence (AI) · Menlo Park$62.0M Series C
4D Molecular Therapeutics
June 2026

4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

Biotechnology · Emeryville$200.0M Post-IPO Debt
Revolution Medicines
April 2026

Revolution Medicines is an innovative and dynamic organization of expert biologists, chemists, pharmacologists, clinical scientists.

Health Care · Redwood City$1.5B Post-IPO Equity
Foghorn Therapeutics
January 2026

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express,

Biopharma · Cambridge$50.0M Post-IPO Equity
Apella Technology
January 2026

Apella Technology is an AI startup that brings modern engineering to improve surgery.

Artificial Intelligence (AI) · Oakland$80.0M Series B
Contineum Therapeutics
December 2025

Contineum Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.

Biotechnology · San Diego$99.2M Post-IPO Equity
Prime Medicine
August 2025

Prime Medicine is a biotechnology company that utilizes Prime Editing to modify genetic sequences to treat a wide range of diseases.

Biotechnology · Cambridge$5.0M Post-IPO Equity
Auron Therapeutics
July 2025

Auron aims to cure cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells.

Biotechnology · NewtonVenture - Series Unknown
A2 Biotherapeutics
May 2025

A2 Biotherapeutics develops T cell therapies targeting solid tumors precisely.

Biotechnology · Agoura Hills$300K Grant
Deepcell
April 2025

Deepcell is a life science company specializing in AI-powered single-cell classification and isolation for basic and translational research.

Artificial Intelligence (AI) · Menlo ParkVenture - Series Unknown
Amplo Biotechnology
January 2025

Amplo Biotechnology is to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction.

Biotechnology · La Jolla$2.9M Grant
Umoja Biopharma
January 2025

Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.

Biopharma · Seattle$100.0M Series C
Xcell Biosciences
December 2024

Xcell Biosciences is a next-generation development and manufacturing platform for enhanced cell therapy performance.

Biotechnology · San Francisco$1.4M Undisclosed
Arzeda
September 2024

Arzeda is a protein design company that creates and manufactures proteins and enzymes for pharmaceuticals and industrial chemicals.

Artificial Intelligence (AI) · Seattle$38.0M Series C
TMRW Life Sciences
July 2024

TMRW Life Sciences provides an integrated platform for automated, software-guided cryospecimen management.

Biotechnology · New York$28.2M Series D
Notch Therapeutics
June 2024

Notch develops immune cell therapy developing a next-generation pipeline that is compatible and focuses on initial cancer cells.

Biotechnology · Toronto$15.5M Venture - Series Unknown
Genomic Life
May 2024

Genomic Life offers genomic products.

Employee Benefits · La Jolla$10.0M Venture - Series Unknown
Voyager Therapeutics
January 2024

Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.

Biotechnology · Cambridge$100.0M Post-IPO Equity
Exscientia
December 2023

Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.

Artificial Intelligence (AI) · Oxford$2.3M Grant
Scribe Biosciences
June 2023

Flexible tools for single cell analysis

Biotechnology · San FranciscoNon-equity Assistance
Orbital Therapeutics
April 2023

Orbital Therapeutics is a biotechnology company that develops RNA-based medicines to treat disease in humans.

Alternative Medicine · Cambridge$270.0M Series A
Octave
October 2025

Octave is a precision care company that provides diagnostic tools and care solutions for neurodegenerative diseases.

Biotechnology · Menlo ParkGrant
CANbridge Pharmaceuticals
August 2025

CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare .

Biotechnology · Beijing$12.7M Post Ipo Equity
BBOT
August 2025

BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3Kα malignancies.

Biopharma · Palo Alto$261.0M Post Ipo Equity

Where Casdin Capital invests

Biotechnology20
Health Care15
Therapeutics9
Life Science8
Medical7
Artificial Intelligence (AI)5

About Casdin Capital's portfolio

How many companies has Casdin Capital invested in?▸

Casdin Capital has invested in 95 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Casdin Capital invest in?▸

Casdin Capital's top investment sectors include Biotechnology, Health Care, Therapeutics, Life Science, Medical. The firm invests across 24 different industry categories.

What is Casdin Capital's largest investment?▸

Among tracked funding rounds, Revolution Medicines received $1.5B in a Post-IPO Equity round. Casdin Capital's total known invested capital is $6.8B.

What is the average investment size for Casdin Capital?▸

Casdin Capital's average investment size is $71.7M across its portfolio of 95 companies.

What are Casdin Capital's most recent investments?▸

Recent Casdin Capital portfolio additions include Hexagon Bio, 4D Molecular Therapeutics, Revolution Medicines, Foghorn Therapeutics, Apella Technology. These companies were founded in 2020 or later.

Reach the founders behind these 95 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →